Asymchem Laboratories (Tianjin) Beheer

Beheer criteriumcontroles 2/4

De CEO Asymchem Laboratories (Tianjin) is Hao Hong, benoemd in Jan2022, heeft een ambtstermijn van 2.83 jaar. bezit rechtstreeks 4.02% van de aandelen van het bedrijf, ter waarde CN¥ 1.20B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 13.3 jaar.

Belangrijke informatie

Hao Hong

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.8yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	13.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Hao Hong's beloning veranderd ten opzichte van Asymchem Laboratories (Tianjin)'s winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	CN¥769m
Jun 30 2024	n/a	n/a	CN¥1b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	n/a	n/a	CN¥2b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Jan 01 2023	n/a	n/a	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥1b
Dec 31 2021	CN¥2m	CN¥2m	CN¥1b
Sep 30 2021	n/a	n/a	CN¥908m
Jun 30 2021	n/a	n/a	CN¥830m
Mar 31 2021	n/a	n/a	CN¥766m
Dec 31 2020	CN¥2m	CN¥2m	CN¥719m
Sep 30 2020	n/a	n/a	CN¥694m
Jun 30 2020	n/a	n/a	CN¥640m
Mar 31 2020	n/a	n/a	CN¥570m
Dec 31 2019	CN¥2m	n/a	CN¥554m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Hao redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de CN markt.

Compensatie versus inkomsten: De beloning van Hao is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Hao Hong (68 yo)

2.8yrs

Tenure

CN¥9,152,000

Compensatie

Dr. Hao Hong, Ph D serves as the Chief Executive Officer of Asymchem Life Science (Tianjin) Co. Ltd. Dr. Hong serves as Chairman, Chief Executive Officer and President of Asymchem Laboratories, Inc. Dr. Ho...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Hao Hong	Founder	2.8yrs	CN¥9.15m	4.02% CN¥ 1.2b
Rui Yang	Co-CEO & Executive Director	2.8yrs	CN¥6.64m	geen gegevens
Da Zhang	CFO, Senior VP & Executive Director	6.3yrs	CN¥5.88m	0.071% CN¥ 21.0m
Liang Hong	Executive VP & Executive Director	2.8yrs	CN¥3.54m	0.0056% CN¥ 1.7m
Xinhui Hu	CTO & CBO	1.8yrs	geen gegevens	geen gegevens
James Randolph Gage	Chief Scientific Officer	2.8yrs	CN¥2.29m	geen gegevens
Chaoyong Chen	Executive Vice President	2.8yrs	CN¥665.70k	0.025% CN¥ 7.6m
Elut Hsu	Senior Vice President of Business Development	no data	geen gegevens	geen gegevens
Pingzhong Huang	Senior Vice President of Process Development	no data	CN¥1.58m	geen gegevens
Changhai Tian	Senior Vice President of 5S Management	no data	geen gegevens	geen gegevens
Jiang Yingwei	Executive Vice President	2.8yrs	geen gegevens	0.071% CN¥ 21.1m
Hsiao Yi	Senior Vice President of Process Development & Application	6.8yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002821 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hao Hong	Founder	13.3yrs	CN¥9.15m	4.02% CN¥ 1.2b
Rui Yang	Co-CEO & Executive Director	13.3yrs	CN¥6.64m	geen gegevens
Da Zhang	CFO, Senior VP & Executive Director	5.6yrs	CN¥5.88m	0.071% CN¥ 21.0m
Liang Hong	Executive VP & Executive Director	13.3yrs	CN¥3.54m	0.0056% CN¥ 1.7m
Ye Song	Non-Executive Director	13.3yrs	CN¥752.00k	geen gegevens
Phil S. Baran	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jin-Quan Yu	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kar Chung Lee	Independent Non Executive Director	3.4yrs	CN¥128.00k	geen gegevens
Xinxin Zhi	Chairman of the Supervisory Committee	13.3yrs	geen gegevens	geen gegevens
Ting Zhang	Non-Executive Director	3.8yrs	CN¥1.93m	0.00087% CN¥ 258.8k
Stephen L. Buchwald	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nicholas Turner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

13.3yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002821 zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.3 jaar).

Asymchem Laboratories (Tianjin) Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Executive VP & Executive Director recently bought CN¥1.8m worth of stock

CFO, Senior VP & Executive Director recently bought CN¥4.3m worth of stock

Asymchem Appoints Cheng Yi Chen as CTO of Small-Molecule Sector

Asymchem Appoints Franck Mevellec as Senior Director, Business Development

Asymchem Laboratories (Tianjin) Co., Ltd., Annual General Meeting, Jun 06, 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024

Recent updates

Asymchem Creates an Artificial Intelligence Platform to Address Key Challenges in Protein Design

Third quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥1.45 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Executive VP & Executive Director recently bought CN¥1.8m worth of stock

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

CFO, Senior VP & Executive Director recently bought CN¥4.3m worth of stock

Second quarter 2024 earnings released: EPS: CN¥0.63 (vs CN¥2.94 in 2Q 2023)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend of CN¥1.80 announced

Asymchem Appoints Cheng Yi Chen as CTO of Small-Molecule Sector

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Approves Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024

Asymchem Appoints Franck Mevellec as Senior Director, Business Development

New major risk - Revenue and earnings growth

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Asymchem Laboratories (Tianjin) Co., Ltd., Annual General Meeting, Jun 06, 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.

Asymchem Laboratories (Tianjin) Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

New major risk - Revenue and earnings growth

Now 23% undervalued after recent price drop

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥1.45 (vs CN¥2.71 in 3Q 2022)

Asymchem Laboratories (Tianjin) Co., Ltd. Appoints Sun Xuejiao as Independent Non-Executive Director

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: CN¥2.94 (vs CN¥3.39 in 2Q 2022)

Asymchem Laboratories (Tianjin) Co., Ltd. Implements Final Cash Dividend (A shares) for 2022, Payable on 21 July 2023

Asymchem Laboratories (Tianjin) Co., Ltd. Declares Final Dividend for the Year Ended 31 December 2022. Payable on 21 July 2023

Full year 2022 earnings released: EPS: CN¥9.02 (vs CN¥3.15 in FY 2021)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Fiscal Year 2022 Results on Mar 31, 2023

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Resignation of Zhang Kun as an Independent Non-Executive Director

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥2.71 (vs CN¥0.79 in 3Q 2021)

Investor sentiment deteriorated over the past week

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) commences an Equity Buyback Plan for CNY 800 million worth of its shares, under the authorization approved on September 2, 2022.

Second quarter 2022 earnings released: EPS: CN¥3.38 (vs CN¥0.81 in 2Q 2021)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Asymchem Laboratories (Tianjin) Co., Ltd. Provides Earnings Guidance for the Period Ended June 30, 2022

Now 27% undervalued after recent price drop

Asymchem Laboratories (Tianjin) Co., Ltd. Approves Cash Dividend for the Year 2021

Now 21% undervalued after recent price drop

Asymchem Laboratories (Tianjin) Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 21 July 2022

Less than half of directors are independent

Asymchem Laboratories (Tianjin) Co., Ltd., Annual General Meeting, Jun 09, 2022

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q1, 2022 Results on Apr 20, 2022

Asymchem Laboratories (Tianjin) Co., Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Final Dividend for the Year Ended December 31, 2021

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) entered into an agreement to acquire remaining 81.82% stake in Snapdragon Chemistry, Inc. for $57.9 million.

Investor sentiment deteriorated over the past week

Asymchem Laboratories (Tianjin) Co., Ltd. Provides Group Earnings Guidance for the Year Ending December 31, 2021

Less than half of directors are independent

Asymchem Laboratories (Tianjin) Co., Ltd. has filed an IPO in the amount of HKD 7.550314 billion.

Asymchem Laboratories (Tianjin) Co., Ltd. Announces Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.47 in 1Q 2020)

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Fiscal Year 2020 Results on Apr 16, 2021

New 90-day low: CN¥256

Asymchem Laboratories (Tianjin) Co., Ltd. Elects Zhang Ting as Non-Independent Director

New 90-day high: CN¥316

New 90-day high: CN¥297

New 90-day high: CN¥288

Asymchem Laboratories (Tianjin) Co., Ltd. to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high: CN¥274

Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) signed an equity transfer agreement to acquire Tianjin Guanqin Pharmaceutical Technology Co., Ltd. from Tianjin Shengqin Pharmaceutical Technology Partnership (Limited Partnership) and Liang Qing for CNY 30 million.

New 90-day high - CN¥250

Asymchem Laboratories (Tianjin) Co., Ltd. to Report First Half, 2020 Results on Aug 08, 2020

Analyse CEO-vergoeding